Sunghwan Kim, PhD
admin2021-03-30T13:56:37+00:00[:ko]보로노이는 글로벌 제약사와 견줄 수 있는 연구 역량과 기술력을 확보해 나아가고 있습니다.[:]
Scientific Advisor: Lillian L. Siu, M.D.
admin2019-08-17T21:17:32+00:00BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada
Scientific Advisor: Pasi A. Jänne, MD, PhD
admin2020-10-22T18:56:32+00:00Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
pasi
admin2019-08-17T20:58:11+00:00Scientific Advisor: Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award, a member of the 2010 AACR Team Science Award and the recipient for the 2018 Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship and in 2018 the European Society of Medical Oncology Translational Research Award and the Outstanding Investigator Award (R35) from the National Cancer Institute. Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance
Lim Jaeyoung / Intellectual Property
admin2020-10-23T11:11:55+00:00Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management." Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management."
Lee Kyungho
admin2020-10-23T11:10:52+00:00(前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab." (前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab."
보로노이의 강점에 대하여
Link-People2020-10-23T11:20:53+00:002018년 3월 하버드와의 기술 이전 및 지분투자 계약을
주도하였으며, 이후로도 글로벌 대형 프로젝트들을
담당하고 있습니다.
Nathanael Gray, PhD
Link-Our-work2021-10-27T19:55:25+00:00Nathanael Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute.
Meet the experts
Link-Company2019-05-09T20:59:55+00:00[:ko]각 분야에서 다년간의 경험과 노하우를 쌓아온 전문가들과 경영진을 소개합니다.[:en]Our experts and the management bring to the team years of experience and expertise in various fields. [:]
